IPSEF News and Press, Ipsen

PARIS, FRANCE, 22 JULY 2026 - Ipsen (Euronext: IPN; ADR: IPSEY) announced today it has completed the acquisition of Memo Therapeutics AG, a late-stage biotech company focused on potravitug, an anti-BK polyomavirus monoclonal antibody. About potravitug Potravitug is a first-in-class monoclon...

Dysport ® achieved statistically significant topline Phase III results, meeting primary endpoints in both episodic (E-BEOND) and chronic (C-BEOND) migraine Dysport is the first botulinum toxin in episodic migraine to demonstrate a statistically significant reduction in monthly migraine day...

2026-07-01 01:24:55 ET More on Ipsen S.A. Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications - Slideshow Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for A...

Acquisition focused on clinical-stage program potravitug, a first-in-class BK polyomavirus monoclonal antibody Totality of evidence from the Phase II SAFE KIDNEY II trial supports initiation of pivotal Phase II/III trial later this year Ipsen expands rare disease portfolio to include serious a...

 IQIRVO ® data expands scientific evidence in fatigue, showing clinically meaningful improvements in patients with moderate-to-severe fatigue at baseline In the first real-world analysis in patients with PBC and an ALP 1-1.67 x ULN, IQIRVO demonstrated a significant ALP reduction, wit...

Phase IV head-to-head, double-blind trial comparing safety and efficacy met its primary and secondary endpoints The DIRECTION trial results show the safety profile for Dysport ® (abobotulinumtoxinA) was non-inferior to Botox ® (onabotulinumtoxinA) in adult patients with upper limb sp...

2026-05-18 19:10:43 ET Ipsen S.A. (IPSEY) Discusses Phase II LANTIC Data and Innovation in Engineered Neuroinhibitors for Aesthetic Indications May 18, 2026 9:00 AM EDT... Read the full article on Seeking Alpha For further details see: Ipsen S.A. (IPSEY) Discusses Phase II L...

Patients treated with corabotase showed a rapid onset of action of 0.84 days and peak effect statistically superior to placebo At Week 24, 60.8% of patients treated with corabotase experienced clinically significant susta...

Corabotase is the first investigational molecule in a newly designated class of recombinant neuroinhibitors, RNI TM , as recognized by the WHO and USAN  Phase II data in glabellar (frown) lines to be featured as a late-breaking presentation at the SCALE Symposium A bro...

2026-04-23 11:41:36 ET Ipsen S.A. (IPSEY) Q1 2026 Earnings Call April 23, 2026 8:00 AM EDT Company Participants David Loew - MD, CEO & Director Aymeric Le Chatelier - Executive VP & CFO Conference Call Participants Yihan Li - Barclays Bank PLC, ...